Nuwellis, Inc., a medical technology company focused on cardiorenal conditions, has closed a public offering raising approximately $6 million. The offering included common stock and warrants, priced around $0.30 per share and warrant. Proceeds will support the company's development and commercialization efforts for its cardiorenal treatment technologies. The offering was managed by Ladenburg Thalmann & Co. and is part of Nuwellis' strategy to expand its market presence and product portfolio in 2026 and beyond.
Nuwellis, a medical technology company focused on cardiorenal conditions, has closed a public offering raising approximately $6 million. The offering included common stock, pre-funded warrants, and Series C and D warrants, with proceeds aimed at supp...
Nuwellis, Inc. announced a public offering of 20 million shares of common stock and accompanying warrants priced at $0.30 each, aiming to raise approximately $6 million. The offering includes Series C and Series D warrants with exercise prices set at...
